Verastem (VSTM)
(Delayed Data from NSDQ)
$13.16 USD
+1.14 (9.48%)
Updated May 14, 2024 04:00 PM ET
After-Market: $13.13 -0.03 (-0.23%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 241 - 260 ( 264 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
2012 Results; All Engines Engaged, Reiterate Buy and $18 PT
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Targeting the Root of the Tumor, Initiating Coverage at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Positions FAK and Mesothelioma as Lead Clinical Program During R&D Update
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Positions FAK and Mesothelioma as Lead Clinical Program During R&D Update
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Verastem Doubles Down on FAK, Picking Up a Phase II-Ready Asset for a Pittance
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Verastem Doubles Down on FAK, Picking Up a Phase II-Ready Asset for a Pittance
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Open Road Ahead for VS-507 as FDA Accepts pCR as an Approvable Endpoint
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Open Road Ahead for VS-507 as FDA Accepts pCR as an Approvable Endpoint
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
FY1Q12 Earnings; Board Additions Bolster Credentials in the CSC Drug Space
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
FY1Q12 Earnings; Board Additions Bolster Credentials in the CSC Drug Space
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Compounds and Stem Cell Science Take Center Stage at AACR
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Compounds and Stem Cell Science Take Center Stage at AACR
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M